I'd be happy with a $10 CVR deal with more to come based on milestones.

Rereading that, it sounds like you're thinking $10 up front?  If so, I see no chance of that.  Any acquiring pharma would be trying to minimize their risk and therefore minimize their upfront payment.  I don't think it would be anywhere near $10. I'd expect $1 or $2 at most.

And as I mentioned in my last post, here's what can happen with a CVR.  Despite what many shareholders see as slow progress to date, at least current management is motivated to move forward as fast as possible and get as much $$$ as possible for shareholders.